Tapering Inhalers and Initiating Biologics Earlier in Severe Asthma

This episode, "Tapering Inhalers and Initiating Biologics Earlier in Severe Asthma," features the panel closing on two unresolved practical questions.

Dr. Chupp asks Dr. Hanania whether he tapers inhalers in patients on biologics, noting the SHAMAL results were dramatic but ran under a year, that most remission data are observational, and that controlled studies suggest perhaps 20% reduce inhaled steroids versus controls. Dr. Hanania says patients announcing they stopped their inhalers freaks him out, partly because insurers want documented inhaler compliance. He reduces the dose but does not stop inhaled steroids completely, noting SHAMAL met its primary endpoint but raised lung function concerns in those who came off entirely, over a period he considered too short. He will not extrapolate across agents with different mechanisms, and awaits ongoing studies. Oral steroids, by contrast, should already be gone. He does not space biologics, though patients ration doses on their own for co-pay reasons, and he awaits the studies Dr. Wechsler and another colleague are pursuing.

Dr. Chupp closes on initiation. Trials enrolled patients on high-dose ICS-LABA who were exacerbating, so the agents are seen as exacerbation-reducers. He asks whether the panel waits for exacerbations, and whether approval becomes difficult otherwise. Dr. Wechsler primarily treats exacerbation-prone patients but will use a biologic for significant symptoms, decrement in lung function, or oral steroid dependence, and finds a symptomatic patient on triple therapy who cannot live fully is usually approvable despite pushback.

Dr. Ross agrees, describing patients who are clinical but do not fit the insurer's box: up all night scratching with atopic dermatitis, or symptomatic with subclinical polyps. Her prescription is documentation. Gather every biomarker and objective measure, including post-bronchodilator FEV1 showing reversibility on appropriate therapy, submit it, and keep appealing. Dr. Chupp thanks the panel and the audience.

Thank you for watching this HCPLive Peer Exchange series on severe asthma and upper airway disease. Please subscribe to our eNewsletter for information on upcoming video series.